RB1 and Familial prostate cancer: Taken together, these results provide a strong rationale that targeting Skp2 by FKB, its derivatives, or proteasome inhibitors (i.e. Bortezomib) should be evaluated as a novel approach for treatment of RB defective, castration resistant prostate cancer.